Zydus Cadila launches Tenglyn - Teneligliptin 20 mg tablets, which belongs to a new class of oral anti-diabetic agents, Gliptins. With an aim to make this important therapy affordable and accessible to diabetic patients, Tenglyn is being priced at just Rs 7 per tablet which is almost 1/6th the price at which the Gliptins were initially launched in India.

Gliptins have shown promise in achieving glycemic control without deteriorating beta cell function and is one of the most recent advancements in diabetes care and management. Research in the field of anti-diabetic therapy seeks to address the problems of hypoglycemia, GI side effects, lactic acidosis, weight gain, CV risks etc., which pose a major challenge in the treatment of diabetes.

Speaking on the development, Dr Sharvil Patel, deputy managing director, Zydus Cadila, said, "At Zydus, our endeavour has been to bring new therapies and innovations that address the two primary challenges in India of accessibility and affordability. Diabetes, as we know, is becoming a major health burden globally. We remain committed to this fight against diabetes and with Tenglyn we provide patients suffering from diabetes access to this advanced treatment at the most affordable cost."